Pharma Aids Limited announcements
270 Dhaka Stock Exchange announcements for Pharma Aids Limited (PHARMAID) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2026 (9).
- Dividend Declaration
(cont. news of PHARMAID): Remarks: The 35% Cash Dividend is recommended keeping in mind the necessity of funds for land acquisition and construction of new factory building as part of the upcoming BMRE project. (end) The Board of Directors has recommended 35% Cash Dividend for the year ended June 30, 2026. Date of AGM: 15.12.2026, Time: 11:30 AM, Venue: Digital Platform. Record Date: 25.11.2026. The Company has also reported an EPS of Tk. 28.05, NAV per share of Tk. 163.31, and NOCFPS of Tk. 24.57 for the year ended June 30, 2026, as against an EPS of Tk. 20.45, NAV per share of Tk. 138.58, and NOCFPS of Tk. 12.74 for the year ended June 30, 2025. (cont.)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company today (04.11.2026) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 03, 2026 at 3:00 PM to consider, among others, annual audited financial statements of the Company for the year ended June 30, 2026.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 6.11 for January-March 2026 as against Tk. 4.45 for January-March 2025; EPS was Tk. 20.20 for July 2025-March 2026 as against Tk. 15.77 for July 2024-March 2025. NOCFPS was Tk. 13.00 for July 2025-March 2026 as against Tk. 5.58 for July 2024-March 2025. NAV per share was Tk. 155.55 as on March 31, 2026 and Tk. 138.58 as on June 30, 2025. (cont.) (Cont. News of PHARMAID): Reasons for deviation: EPS has increased compared to previous year's 3rd quarter due to increase in sales, resulting from expansion of production capacity. NOCFPS increased due to increase in collection. NAVPS increased due to increase in retained earnings. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
- Transmission of Deceased Sponsor Director's Shares to Successors
The Company has informed that 149,500 shares held by Late M. A. Masud, a Sponsor Director and former Chairman of the Company, who passed away on 11.11.2025, will be transmitted among his successors in accordance with the Succession Certificate issued by the Honorable Court. The names of the successors, their relationships with the deceased shareholder, and the number of shares to be received by each successor are as follows: (cont.) (Cont. news of PHARMAID): 1. Mrs. Shahinoor Baby, Wife, Sponsor Director and Chairman of the Company, will receive 18,688 shares; 2. Mr. Md. Nurul Mahbub, Son, will receive 52,325 shares; 3. Mrs. Farzina Binty Masud, Daughter, will receive 26,162 shares; and 4. Mr. Mahir Musleh, Son, will receive 52,325 shares. (end)
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 7.28 for October-December 2025 as against Tk. 5.66 for October-December 2024; EPS was Tk. 14.09 for July-December 2025 as against Tk. 11.32 for July-December 2024. NOCFPS was Tk. 10.11 for July-December 2025 as against Tk. 4.93 for July-December 2024. NAV per share was Tk. 149.54 as on December 31, 2025 and Tk. 138.58 as on June 30, 2025. (cont.) (Cont. News of PHARMAID): Reasons for deviation: EPS has increased compared to previous year's 2nd quarter mostly due to increase in sales, resulting from expansion of production capacity. NOCFPS increased due to increase in collection. NAV has increased due to increase in retained earnings. (end)
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.